Introduction
============

The balance between cerebral oxygen supply and demand is necessary for the brain to maintain normal physiological activity. Patients with severe traumatic brain injury (sTBI) exhibit serious cerebral oxygen metabolism dysfunction at an early stage, which is a leading cause of mortality. Appropriate treatment for maintaining the cerebral oxygen supply-demand balance and reducing the relevant complications has great clinical significance ([@b1-etm-07-06-1683]). The body is in a state of inflammation following sTBI and the serum C-reactive protein (CRP) level increases rapidly, exacerbating the pathological damage ([@b2-etm-07-06-1683],[@b3-etm-07-06-1683]). CRP has been reported to be a sensitive indicator that reflects cerebral trauma severity ([@b4-etm-07-06-1683]). Ulinastatin, a protease inhibitor, is predominantly used to treat acute and chronic pancreatitis. It has been reported that ulinastatin exhibits cerebral protective effects and may inhibit the release of inflammatory mediators, however, there is limited research on the use of ulinastatin in the treatment for sTBI ([@b5-etm-07-06-1683]). Therefore, the present study focused on the application of ulinastatin in the treatment of sTBI and investigated the effects of ulinastatin on cerebral oxygen metabolism and the level of CRP.

Subjects and methods
====================

Subjects
--------

In total, 92 patients admitted to the Intensive Care Unit (ICU) in the First Affiliated Hospital of Xinxiang Medical University (Xinxiang, China) between February 2010 and May 2013 with a clinical diagnosis of sTBI were enrolled in the study. Patients were included in the study if the following criteria were met: Diagnosis of sTBI by computed tomography or magnetic resonance imaging; Glasgow Coma Scale (GCS) score of \<8; and admittance to ICU within 8 h after injury ([@b6-etm-07-06-1683]). Exclusion criteria included combined brain complications, combined severe injury and patient mortality within seven days following injury ([@b7-etm-07-06-1683]). A total of 92 patients with sTBI were randomly divided into two groups (n=46 per group). The male-to-female ratio, age range, average age and GCS score in the control group were 41:5, 28--63 years, 45.27±15.33 years and 5.49±0.71, respectively, while in the observation group, the parameters were 39:7, 25--61 years, 43.19±15.60 years and 5.52±0.74, respectively. The gender ratio, age and GCS score of the two groups exhibited no statistically significant differences (P\>0.05). The study was conducted in accordance with the Declaration of Helsinki and with approval from the Ethics Committee of the First Affiliated Hospital of Xinxiang Medical University. Written informed consent was obtained from all the participants.

Treatment
---------

All the patients admitted to the ICU were administered conventional therapy, including ventilator-assisted therapy, oxygen therapy, intracranial pressure reduction, dehydration, bleeding control, neuroprotection and appropriate symptomatic treatments. The control group received conventional therapy plus a placebo (0.9% sodium chloride), while the observation group received conventional therapy plus ulinastatin (200,000 units; Techpool Bio-Pharma Co., Ltd, Guangzhou, China) via intravenous injection twice a day for seven days.

Cerebral oxygen metabolism monitoring
-------------------------------------

Cerebral oxygen metabolism was monitored as previously described ([@b8-etm-07-06-1683]). Arterial and jugular venous blood was collected in the morning for blood gas analysis (ABL80; Radiometer Medical ApS, Copenhagen, Denmark). The parameters recorded included hemoglobin concentration (Hb), jugular venous blood lactate (JVBL), arterial oxygen saturation (SaO~2~), jugular venous bulb oxygen saturation (SjvO~2~), partial pressure of O~2~ in the arterial blood (PaO~2~) and partial pressure of O~2~ in the jugular venous blood (PjvO~2~). Parameters were calculated as follows: Arterial oxygen content (CaO~2~) = (Hb × 1.36 × SaO~2~) + (0.003 × PaO~2~); venous oxygen content (CjvO~2~) = (Hb × 1.36 × SjvO~2~) + (0.003 × PjvO~2~); arteriovenous oxygen content difference (AVDO~2~) = CaO~2~ - CjvO~2~; and cerebral extraction of oxygen (CEO~2~) = 1 - (CjvO~2~/CaO~2~).

Assay of CRP level
------------------

Peripheral blood was collected from the patients on day 1, 3, 5 and 7 in the morning and the CRP levels were determined using an ELISA kit, according to the manufacturer's instructions (Shanghai Hengyuan Biotechnology Co., Ltd, Shanghai, China).

Statistical analysis
--------------------

Data were analyzed using SPSS 15.0 software (SPSS, Inc., Chicago, IL, USA) and all the data are expressed as the mean ± standard deviation. Data were analyzed using the unpaired Student's t test for comparisons between two groups and the χ^2^ test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Comparison of cerebral oxygen metabolism parameters between the two groups
--------------------------------------------------------------------------

JVBL, SjvO~2~, AVDO~2~ and CEO~2~ measurements for the two groups are shown in [Table I](#tI-etm-07-06-1683){ref-type="table"}. As shown in [Fig. 1](#f1-etm-07-06-1683){ref-type="fig"}, the level of JVBL in the control group decreased as compared with the level at day 1, however, no statistically significant differences were observed (P\>0.05). By contrast, the observation group exhibited a significant decrease in JVBL levels (P\<0.05) when compared with the level on day 1, and the levels were also lower compared with the control group (P\<0.05). The value of SjvO~2~ in the patients increased following injury and peaked on day 3. Statistically significant differences were observed between the two groups with regard to SjvO~2~ on day 3, 5 and 7 ([Fig. 2](#f2-etm-07-06-1683){ref-type="fig"}). The AVDO~2~ level in the two groups decreased, and statistically significant differences were observed between the groups ([Fig. 3](#f3-etm-07-06-1683){ref-type="fig"}). In addition, the CEO~2~ level in the two groups decreased, with the level in the control group decreasing significantly as compared with observation group ([Fig. 4](#f4-etm-07-06-1683){ref-type="fig"}).

Comparison of the CRP levels between the two groups
---------------------------------------------------

As shown in [Table II](#tII-etm-07-06-1683){ref-type="table"}, the CRP levels of the two groups increased and peaked on day 3 in the observation group. The CRP levels in the observation group significantly decreased on day 5 (35.27±15.18 mg/l) and day 7 (22.65±10.48 mg/l), and were lower than the values observed in the control group (56.19±13.24 mg/l and 47.36±15.73 mg/l, respectively); statistically significant differences were observed between the two groups (P\<0.05).

Comparison of gastrointestinal bleeding and mortality rates between the two groups
----------------------------------------------------------------------------------

Gastrointestinal bleeding and mortality rates were also recorded for 30 days. In the control group, 20 patients (43.48%) showed gastrointestinal bleeding and 15 patients (32.61%) succumbed to their illness. In the observation group, only 11 patients (23.91%) showed gastrointestinal bleeding and eight mortalities (17.39%) were recorded. Statistically significant differences were observed when compared with the control group (P\<0.05).

Discussion
==========

Cerebral ischemia-hypoxia occurs following the development of sTBI. Since the cerebral oxygen metabolism indicators, including JVBL, SjvO~2~, AVDO~2~ and CEO~2~, reflect the state of cerebral microcirculation and oxygen supply-demand, monitoring the associated indicators is an effective method for the early detection of cerebral ischemia and hypoxia ([@b9-etm-07-06-1683]). In addition, the body is in a state of inflammation with increased serum CRP levels following sTBI, and the serum CRP levels decrease when the body is recovered ([@b10-etm-07-06-1683]). Ulinastatin, as a protease inhibitor, has significant anti-inflammatory effects and has been used to treat pancreatitis. Recently, clinical studies have revealed that ulinastatin improves the circulation of shock caused by cell damage and exhibits cerebral protective effects ([@b11-etm-07-06-1683]). To date, there has been limited clinical use of ulinastatin in the treatment of sTBI. Thus, the present study aimed to investigate the effects of ulinastatin on cerebral oxygen metabolism and CRP levels.

A decrease of blood flow in cerebral circulation induces the brain tissue to draw oxygen from the blood at a higher proportion in order to maintain normal metabolism. By contrast, when the blood flow increases, the proportion of oxygen drawn from blood decreases, which results in increased oxygen content in cerebral circulation ([@b12-etm-07-06-1683]). Since the internal jugular vein is the main channel of cerebral circulation, blood gas analysis of the internal jugular vein indirectly reflects cerebral oxygen metabolism (elevated SjvO~2~ indicates hyperemia in the brain). AVDO~2~ and CEO~2~, calculated using Fick's equations, directly reflect the cerebral microcirculation and oxygen supply-demand ([@b13-etm-07-06-1683],[@b14-etm-07-06-1683]). The results of the present study revealed that ulinastatin decreases the levels of JVBL and AVDO~2~ and increases the levels of SjvO~2~ and CEO~2~ in patients with sTBI. These results further demonstrate that ulinastatin improves cerebral ischemia-hypoxia and enhances the utilization of oxygen ([@b15-etm-07-06-1683]). A previous study reported that ulinastatin reduces the rate of mortality by decreasing gastrointestinal bleeding and protecting immunological and renal functions ([@b16-etm-07-06-1683]). The results of the present study demonstrated that the CRP level increased rapidly following sTBI and ulinastatin administration lowered the CRP level significantly. Less gastrointestinal bleeding and a lower mortality rate was observed in the observation group, indicating that ulinastatin is effective in the treatment of sTBI. The potential mechanism of ulinastatin with regard to the treatment of sTBI may involve the clearance of oxygen free radicals and inhibiting the release of lysosomal enzymes and inflammatory mediators ([@b17-etm-07-06-1683]).

In conclusion, ulinastatin administration effectively improves the prognosis of patients with sTBI by improving cerebral oxygen metabolism, lowering the CRP level and reducing gastrointestinal bleeding and the mortality rate.
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###### 

Comparison of cerebral oxygen metabolism parameters between the two groups.

  Groups        Index            Day 1         Day 3                                                                                                      Day 5                                                                                                     Day 7
  ------------- ---------------- ------------- ---------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Observation   JVBL (mmol/l)    3.58±1.14     2.53±0.69[a](#tfn1-etm-07-06-1683){ref-type="table-fn"},[b](#tfn2-etm-07-06-1683){ref-type="table-fn"}     1.46±0.53[a](#tfn1-etm-07-06-1683){ref-type="table-fn"},[b](#tfn2-etm-07-06-1683){ref-type="table-fn"}    1.32±0.39[a](#tfn1-etm-07-06-1683){ref-type="table-fn"},[b](#tfn2-etm-07-06-1683){ref-type="table-fn"}
                SjvO~2~ (%)      51.49±7.21    71.47±7.85[a](#tfn1-etm-07-06-1683){ref-type="table-fn"},[b](#tfn2-etm-07-06-1683){ref-type="table-fn"}    68.21±5.48[a](#tfn1-etm-07-06-1683){ref-type="table-fn"},[b](#tfn2-etm-07-06-1683){ref-type="table-fn"}   63.36±5.13[a](#tfn1-etm-07-06-1683){ref-type="table-fn"},[b](#tfn2-etm-07-06-1683){ref-type="table-fn"}
                AVDO~2~ (ml/l)   69.18±14.32   39.56±11.39[a](#tfn1-etm-07-06-1683){ref-type="table-fn"},[b](#tfn2-etm-07-06-1683){ref-type="table-fn"}   45.38±9.24[a](#tfn1-etm-07-06-1683){ref-type="table-fn"},[b](#tfn2-etm-07-06-1683){ref-type="table-fn"}   48.26±12.43[a](#tfn1-etm-07-06-1683){ref-type="table-fn"},[b](#tfn2-etm-07-06-1683){ref-type="table-fn"}
                CEO~2~ (%)       48.48±4.52    36.25±5.83[a](#tfn1-etm-07-06-1683){ref-type="table-fn"},[b](#tfn2-etm-07-06-1683){ref-type="table-fn"}    39.13±5.23[a](#tfn1-etm-07-06-1683){ref-type="table-fn"},[b](#tfn2-etm-07-06-1683){ref-type="table-fn"}   40.18±5.47[b](#tfn2-etm-07-06-1683){ref-type="table-fn"}
  Control       JVBL (mmol/l)    3.52±1.12     3.47±0.72                                                                                                  3.05±0.44                                                                                                 2.85±0.36
                SjvO~2~ (%)      50.83±7.05    61.52±6.59[a](#tfn1-etm-07-06-1683){ref-type="table-fn"}                                                   60.72±5.22[a](#tfn1-etm-07-06-1683){ref-type="table-fn"}                                                  54.27±5.06
                AVDO~2~ (ml/l)   67.55±13.40   49.41±12.18[a](#tfn1-etm-07-06-1683){ref-type="table-fn"}                                                  53.19±7.32[a](#tfn1-etm-07-06-1683){ref-type="table-fn"}                                                  55.45±13.30
                CEO~2~ (%)       48.39±4.43    25.19±5.07[a](#tfn1-etm-07-06-1683){ref-type="table-fn"}                                                   31.46±4.92[a](#tfn1-etm-07-06-1683){ref-type="table-fn"}                                                  32.43±4.15[a](#tfn1-etm-07-06-1683){ref-type="table-fn"}

P\<0.05, vs. day 1 in the same group;

P\<0.05, vs. control group.

JVBL, jugular venous blood lactate; SjvO~2~, jugular venous bulb oxygen saturation; AVDO~2~, arteriovenous oxygen content difference; CEO~2~, cerebral extraction of oxygen.

###### 

Comparison of the CRP levels between the two groups (mg/l).

  Groups               Day 1         Day 3         Day 5                                                       Day 7
  -------------------- ------------- ------------- ----------------------------------------------------------- -----------------------------------------------------------
  Observation (n=46)   32.15±10.28   51.46±11.39   35.27±15.18[a](#tfn4-etm-07-06-1683){ref-type="table-fn"}   22.65±10.48[a](#tfn4-etm-07-06-1683){ref-type="table-fn"}
  Control (n=46)       31.49±10.07   47.22±12.36   56.19±13.24                                                 47.36±15.73

P\<0.05, vs. control group.

CRP, C-reactive protein.
